FCA
GALT icon

Fortis Capital Advisors’s Galectin Therapeutics GALT Stock Holding History

Fortis Capital Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.6K Sell
14,139
-92,000
-87% -$238K 0.01% 403
2026
Q1 		$296K Hold
106,139
– – 0.04% 302
2025
Q4 		$442K Buy
+106,139
New +$559K 0.07% 208

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fortis Capital Advisors's GALT Position: Q2 2026 in Review

Fortis Capital Advisors reduced its Galectin Therapeutics (GALT) stake by 87% in Q2 2026, selling an estimated $238K and leaving 14,139 shares worth $65.6K. The position accounts for 0.01% of the portfolio, ranked #403.

Fortis Capital Advisors first reported a position in GALT in Q4 2025 and has held it in 3 quarters since. The position peaked at $442K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Fortis Capital Advisors held 14,139 shares of Galectin Therapeutics worth $65.6K as of Q2 2026.
  • Fortis Capital Advisors sold 92,000 Galectin Therapeutics shares in Q2 2026, an estimated $238K.
  • Galectin Therapeutics made up 0.01% of Fortis Capital Advisors's portfolio in Q2 2026, its #403 holding.
  • Fortis Capital Advisors first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Fortis Capital Advisors's Galectin Therapeutics position peaked at $442K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Fortis Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.